Shots:
- The Chinese NMPA has approved Akeso’s gumokimab (AK111; SC, 17 doses per year, incl. loading) to treat mod. to sev. plaque psoriasis in adults based on the P-III (AK111-301) trial & 3 supportive studies, showing rapid improvement in 2wks.
- Data showed short-term efficacy, with a PASI 75 response rate approaching 94.6% & PASI 100 reaching 47.7% at 12wks. Also, long-term efficacy for over 52wks. showed PASI 75 response approaching 100% & PASI 100 improved to 68.9%
- Additionally, the NMPA has accepted the sNDA of gumokimab for the treatment of active ankylosing spondylitis (AS)
Ref: PRnewswire | Image: Akeso | Press Release
Related News: Akeso Presents the P-III (HARMONi-6) Trial Data on Ivonescimab + CT in 1L Squamous NSCLC at ASCO 2026
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
